CSF3R and chronic neutrophilic leukemia: Acting downstream of JAK kinases, STAT3 could bypass the inhibitory effects of ruxolitinib, whereas co-operation of RUNX1 with CSF3R mutations might be involved in CNL disease progression and AML transformation.